Boehringer Ingelheim looks to Korean biotech for next drug breakthroughs

Korea is moving beyond its traditional role as a market for medicines to become a source of pharmaceutical innovation, with local biotech partnerships and clinical research expected to play a larger role in global drug development, Boehringer Ingelheim CEO Shashank Deshpande says. “We do not anymore see Korea just f…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.